By Josh Beckerman 
 

Liquidia Technologies Inc. (LQDA), which reached a broad, multiyear collaboration with GlaxoSmithKline (GSK) in 2012, has amended the agreement for development of products using Liquidia's PRINT technology.

The amended agreement gives Liquidia the right to develop and commercialize three additional PRINT-based therapeutics delivered via inhalation. Additionally, Liquidia can acquire rights to pursue additional PRINT-based programs, subject to GlaxoSmithKline approval.

Liquidia's lead product candidate is LIQ861, a dry powder formulation of treprostinil that is being evaluated for the treatment of pulmonary arterial hypertension. The company said Wednesday that submitting an LIQ861 New Drug Application is its top priority for 2019, but "we also see clear opportunities to further expand the Liquidia pipeline of respiratory products."

Liquidia's initial public offering was in July 2018.

 

Write to Josh Beckerman at josh.beckerman@wsj.com

 

(END) Dow Jones Newswires

June 26, 2019 19:13 ET (23:13 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more GSK Charts.